Atea Pharmaceuticals Inc. has announced new modeling data supporting its fixed-dose combination regimen of bemnifosbuvir (BEM) and ruzasvir (RZR) for the treatment of hepatitis C virus (HCV) infection. The data predict that the BEM and RZR combination can achieve near-complete inhibition of viral replication, with a modeled time to cure of approximately 7 to 8 weeks. These findings reinforce Phase 2 study results, which showed sustained virologic response rates at 12 weeks post-treatment (SVR12) of 98% in the per-protocol treatment-adherent population and 95% in all patients regardless of adherence after 8 weeks of treatment. The new data were presented at The Liver Meeting® 2025, held by the American Association for the Study of Liver Diseases (AASLD) from November 7-11, 2025, in Washington, DC. The company is currently using the fixed-dose combination in an ongoing Phase 3 program.